Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMedbot-B
Stock Code02252
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities設計、開發及商業化手術機器人,以協助外科醫生完成複雜的外科手術。公司是全球行業中唯一一家擁有覆蓋五大主要及快速增長手術專科(即腔鏡、骨科、泛血管、經自然腔道及經皮穿刺手術)產品組合的公司。
Listing Date2021-11-02
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市中國(上海)自由貿易試驗區張東路1601號1幢B區101室
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitemedbotsurgical.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 43.20 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 21,600
Par ValueRMB 1.0 / shares
Offer Period2021-10-21 to 2021-10-26
Global Offering Shares36,200,000 shares
HK Public Offer Shares (Initial)3,620,000 shares (10.0%)
Public Offer Lots (Initial)7,240lots (Pool A3,620lots,Pool B3,620lots)
International Placing Shares (Initial)32,580,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO953,163,831 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share45.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,563,840,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 21,600
2 lots 1,000 HK$ 43,200
3 lots 1,500 HK$ 64,800
4 lots 2,000 HK$ 86,400
5 lots 2,500 HK$ 108,000
6 lots 3,000 HK$ 129,600
7 lots 3,500 HK$ 151,200
8 lots 4,000 HK$ 172,800
9 lots 4,500 HK$ 194,400
10 lots 5,000 HK$ 216,000
12 lots 6,000 HK$ 259,200
14 lots 7,000 HK$ 302,400
16 lots 8,000 HK$ 345,600
18 lots 9,000 HK$ 388,800
20 lots 10,000 HK$ 432,000
30 lots 15,000 HK$ 648,000
40 lots 20,000 HK$ 864,000
50 lots 25,000 HK$ 1,080,000
60 lots 30,000 HK$ 1,296,000
70 lots 35,000 HK$ 1,512,000
80 lots 40,000 HK$ 1,728,000
90 lots 45,000 HK$ 1,944,000
100 lots 50,000 HK$ 2,160,000
110 lots 55,000 HK$ 2,376,000
120 lots 60,000 HK$ 2,592,000
130 lots 65,000 HK$ 2,808,000
140 lots 70,000 HK$ 3,024,000
150 lots 75,000 HK$ 3,240,000
160 lots 80,000 HK$ 3,456,000
170 lots 85,000 HK$ 3,672,000
180 lots 90,000 HK$ 3,888,000
190 lots 95,000 HK$ 4,104,000
200 lots 100,000 HK$ 4,320,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
400 lots 200,000 HK$ 8,640,000
600 lots 300,000 HK$ 12,960,000
800 lots 400,000 HK$ 17,280,000
1,000 lots 500,000 HK$ 21,600,000
1,200 lots 600,000 HK$ 25,920,000
1,400 lots 700,000 HK$ 30,240,000
1,600 lots 800,000 HK$ 34,560,000
1,800 lots 900,000 HK$ 38,880,000
2,000 lots 1,000,000 HK$ 43,200,000
2,400 lots 1,200,000 HK$ 51,840,000
2,800 lots 1,400,000 HK$ 60,480,000
3,200 lots 1,600,000 HK$ 69,120,000
3,620 lots 1,810,000 HK$ 78,192,000
16,637 lots 8,318,686 HK$ 359,367,235

Stock Connect Inclusion Analysis

HK Market Cap HK$ 24.95B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 37,745,287,708
H-Share Market Cap (at Offer Price)HK$ 40,891,577,241
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣209.3百萬元
Period-End Cash Balance人民幣1,497.3百萬元
Listing Expenses~HK$ 101,220,000
Listing Expenses / Funds Raised~6.47%
Total Pre-IPO Investment人民幣15億元

Financial Data

Unit: RMB
Income Statement
Item 20192020
Profit for the year -768-969
Balance Sheet
Item 20192020
Cash and cash equivalents 643603
Inventories 00
Total current assets 601899
Total current liabilities 927921
Total equity 509924
Equity attributable to owners 503922
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 45.8
First Day OpenHK$ 39.8
First Day Change6.02%
First Day Volume21828600.0
First Day Turnover960977000.0
Use of Proceeds
1、約510.1百萬港元(占35.0%)將用于我們的核心產品圖邁; 2、約306.1百萬港元(占21.0%)將用于我們的骨科手術機器人; 3、約276.9百萬港元(占19.0%)將用于我們其他候選產品; 4、約72.9百萬港元(占5.0%)將用于提高制造與供應鏈管理能力; 5、約145.7百萬港元(占10.0%)將用于擴大我們的產品組合; 6、約145.7百萬港元(占10.0%)將用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
J.P. Morgan Securities (Far East) Limited CE AAB026 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (2)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (4)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137 Livermore Holdings Limited CE BJN764

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Artisan China Post-Venture Master Fund LP 37,065,600 HKD — 2.40% — 6 months 2022-05-02
2 Aspex Master Fund 148,154,400 HKD — 9.50% — 6 months 2022-05-02
3 CloudAlpha Master Fund 74,066,400 HKD — 4.70% — 6 months 2022-05-02
4 Hillhouse Funds 111,110,400 HKD — 7.10% — 6 months 2022-05-02
5 LAV Star Limited 111,110,400 HKD — 7.10% — 6 months 2022-05-02
6 Snow Lake China Master Fund, Ltd. 111,110,400 HKD — 7.10% — 6 months 2022-05-02
7 Yorkool International Limited 111,110,400 HKD — 7.10% — 6 months 2022-05-02

Directors & Management

PositionChinese nameEnglish Name
Chairman孫洪斌—
Company Secretary許燕珊—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東上海默化、上海擎禎、微創投資及微創醫療,緊隨全球發售完成後合共控制本公司股本總額約52.53%(不計超額配股權);何超博士及其配偶合計擁有約65.24%權益。
About this page

This page shows Medbot-B (02252) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect